We are answering impossibility’s call.
Nexcyon is advancing veterinary medicine and improving the quality of life for companion animals around the world.
Scroll down to learn more
This is the art of entelechy.
The point where possibility meets determination and potential is fully realized.
It's a place without tape or glue or shortcuts. Where scientific solutions present an elegant simplicity–and contain hidden complexity.
Hard work, ingenuity and the accumulated lessons taught by thoughtful analysis and adventurous curiosity. Like origami, we believe transformative scientific discovery is a sum made greater by its parts.
Interesting things happen at the edge of what’s imaginable.
An independent pharmaceuticals company, Nexcyon meets the challenge of breakthrough science with true innovation, creativity and a holistic approach to the research and development of new medicines, delivery systems and therapeutics.
One thing we’ve learned: discovery does not stop to consider the odds.
Our success is built at the bench. And our understanding advances with every experiment.
Explore our selected list of peer-reviewed scientific and medical journal articles, all authored by Nexcyon scientists.
NEW: The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical studyJ. vet. Pharmacol. Therap. 2013; doi: 10.1111/jvp.12096
NEW: Evidence-Based Medicine: The Design and Interpretation of Noninferiority Clinical Trials in Veterinary MedicineJ Vet Intern Med 2013; 27:1305-1317
The history and pharmacology of fentanyl: relevance to a novel, long-acting transdermal fentanyl solution newly approved for use in dogsJ. vet. Pharmacol. Therap. 2012; 35 (Suppl. 2), 3–19.
Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory BeaglesJ. vet. Pharmacol. Therap. 2012; 35 (Suppl. 2), 21–26.
Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory BeaglesJ. vet. Pharmacol. Therap. 2012; 35 (Suppl. 2), 27–33.
The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogsJ. vet. Pharmacol. Therap. 2012; 35 (Suppl. 2), 35–43.
Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory BeaglesJ. vet. Pharmacol. Therap. 2012; 35 (Suppl. 2), 45–51.
The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical studyJ. vet. Pharmacol. Therap. 2012; 35 (Suppl. 2), 53–64.
Population pharmacokinetics of transdermal fentanyl solution following a single dose administered prior to soft tissue and orthopedic surgery in dogsJ. vet. Pharmacol. Therap. 2012; 35 (Suppl. 2), 65–72.
Our historic new headquarters is at the center of a burgeoning biotech hotspot, in the heart of one of the Midwest’s most beautiful cities.
Built on an isthmus between Lakes Monona and Mendota, Madison, Wisconsin, is a capital city blessed with incredible natural beauty, a major university and a vibrant creative culture. It also boasts the fastest growing biotech community in the country, according to Battelle/BIO’s 2012 State Bioscience Industry Development report.
A global company, Nexcyon maintains offices in London, UK, and strategic partnerships throughout North America, Western Europe, Australia and New Zealand.
Revolutionizing tomorrow doesn’t happen overnight.
At Nexcyon, we work closely with the world’s leading biotech and pharmaceutical companies to find new therapies that address the underserved areas of veterinary medicine. Our expertise, resources and proven track record make us the perfect partner for bringing innovative products to market–including new small molecules, biopharmaceuticals, novel delivery technologies and devices, even existing products that could be adapted for animal health use.
We are currently interested in acquiring products that have already been approved or are still in development. We are also open to in-licensing or forming a collaborative arrangement to obtain veterinary claims and provide a revenue stream for your business.
Start the conversation. Contact Irene Clark at 608.210.8060 or email@example.com today.